By Siddhi Mahatole April 20 (Reuters) - U.S. drugmaker Eli Lilly has agreed to buy privately held biotech firm Kelonia ...

Eli Lilly’s deal for Kelonia, which develops blood cancer therapies, could come as early as Monday.

B for Kelonia adds a credible in vivo CAR-T platform aimed at multiple myeloma, with a one-time IV delivery and no ...

The deal secures Lilly an in vivo gene therapy platform that could make CAR-T cell therapies accessible to a far broader ...